The Efficacy and Safety of Idelalisib- Gilead GS-US-312-0123

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

• IRAS ID

  146881

• Contact name

  Anna Schuh

• Contact email

  anna.schuh@ndcls.ox.ac.uk

• Sponsor organisation

  Gilead Sciences, Inc.

• Eudract number

  2013-003313-17

• Clinicaltrials.gov Identifier

  NCT01980888

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  14/SC/0178

• Date of REC Opinion

  2 Jun 2014

• REC opinion

  Further Information Favourable Opinion